Characterization of hepatitis C RNA-containing particles from human liver by density and size.
Hepatitis C virus (HCV) particles found in vivo are heterogeneous in density and size, but their detailed characterization has been restricted by the low titre of HCV in human serum. Previously, our group has found that HCV circulates in blood in association with very-low-density lipoprotein (VLDL). Our aim in this study was to characterize HCV RNA-containing membranes and particles in human liver by both density and size and to identify the subcellular compartment(s) where the association with VLDL occurs. HCV was purified by density using iodixanol gradients and by size using gel filtration. Both positive-strand HCV RNA (present in virus particles) and negative-strand HCV RNA (an intermediate in virus replication) were found with densities below 1.08 g ml(-1). Viral structural and non-structural proteins, host proteins ApoB, ApoE and caveolin-2, as well as cholesterol, triglyceride and phospholipids were also detected in these low density fractions. After fractionation by size with Superose gel filtration, HCV RNA and viral proteins co-fractionated with endoplasmic reticulum proteins and VLDL. Fractionation on Toyopearl, which separates particles with diameters up to 200 nm, showed that 78 % of HCV RNA from liver was >100 nm in size, with a positive-/negative-strand ratio of 6 : 1. Also, 8 % of HCV RNA was found in particles with diameters between 40 nm and 70 nm and a positive-/negative-strand ratio of 45 : 1. This HCV was associated with ApoB, ApoE and viral glycoprotein E2, similar to viral particles circulating in serum. Our results indicate that the association between HCV and VLDL occurs in the liver.
Nielsen
Søren U
SU
Liver Research Group, Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Bassendine
Margaret F
MF
Liver Research Group, Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Martin
Caroline
C
Liver Research Group, Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Lowther
Daniel
D
Liver Research Group, Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Purcell
Paul J
PJ
Liver Research Group, Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
King
Barnabas J
BJ
Liver Research Group, Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Neely
Dermot
D
Department of Clinical Biochemistry, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Toms
Geoffrey L
GL
Liver Research Group, Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
D002462:Cell Membrane / Q000737:chemistry / Q000821:virology; D002499:Centrifugation, Density Gradient; D002850:Chromatography, Gel; D017074:Common Variable Immunodeficiency / Q000821:virology; D016174:Hepacivirus / Q000737:chemistry / Q000235:genetics / Q000302:isolation & purification* / Q000502:physiology; D006526:Hepatitis C / Q000821:virology; D006801:Humans; D008079:Lipoproteins, VLDL / Q000032:analysis*; D008099:Liver / Q000821:virology*; D012367:RNA, Viral / Q000032:analysis* / Q000097:blood / Q000235:genetics / Q000302:isolation & purification; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014764:Viral Proteins / Q000032:analysis; D014771:Virion / Q000737:chemistry / Q000235:genetics* / Q000302:isolation & purification
D008079:Lipoproteins, VLDL; D012367:RNA, Viral; D014764:Viral Proteins
J Viral Hepat. 1996 Jan;3(1):11-7
8736235
J Biol Chem. 2008 Jan 11;283(2):849-54
18003621
J Virol Methods. 2004 Mar 1;116(1):103-6
14715313
J Virol. 2008 Mar;82(5):2120-9
18077707
Clin Chem. 1993 Nov;39(11 Pt 1):2276-81
8222220
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5848-53
17376867
Science. 2005 Jul 22;309(5734):623-6
15947137
J Biol Chem. 2003 May 2;278(18):15998-6007
12591929
Trends Cell Biol. 2002 Nov;12(11):517-23
12446113
J Biol Chem. 2007 Dec 21;282(51):37158-69
17942391
J Virol. 1997 Sep;71(9):6650-61
9261387
J Virol. 2003 Apr;77(7):4160-8
12634374
Biol Cell. 2004 Mar;96(2):103-8
15116740
Med Microbiol Immunol. 1993 Dec;182(6):329-34
8121333
Am J Pathol. 2003 Aug;163(2):433-44
12875965
J Nutr. 1999 Feb;129(2S Suppl):463S-466S
10064310
Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2561-6
15699349
J Virol. 2002 Jul;76(14):6919-28
12072493
Science. 1999 Jul 2;285(5424):110-3
10390360
J Virol. 2005 Nov;79(21):13594-605
16227280
Virology. 2005 Jun 5;336(2):144-53
15892956
J Virol. 2007 Dec;81(24):13783-93
17913825
J Hepatol. 1998 Jul;29(1):1-11
9696486
J Biol Chem. 2002 Aug 23;277(34):31187-200
12065576
J Biol Chem. 1957 May;226(1):497-509
13428781
J Gen Virol. 2004 Jun;85(Pt 6):1497-1507
15166434
J Gen Virol. 2006 Oct;87(Pt 10):2983-2991
16963757
J Gen Virol. 2005 Mar;86(Pt 3):677-685
15722528
J Virol Methods. 1999 Jan;77(1):1-9
10029319
Anal Biochem. 1999 Dec 1;276(1):88-96
10585748
Nat Cell Biol. 2007 Sep;9(9):1089-97
17721513
Nat Rev Microbiol. 2007 Jun;5(6):453-63
17487147
J Clin Pathol. 2006 Feb;59(2):174-8
16443734
Hepatol Res. 2001 Jul;20(3):335-347
11404193
Anal Biochem. 1994 Aug 1;220(2):367-73
7978280
Clin Exp Immunol. 1997 Oct;110(1):4-8
9353141
J Gen Virol. 2003 Oct;84(Pt 10):2761-2769
13679611
J Med Virol. 2001 Jul;64(3):334-9
11424123
J Hepatol. 1995 Apr;22(4):440-8
7665862
Virology. 2004 Jul 1;324(2):450-61
15207630
J Biol Chem. 2003 Jul 4;278(27):24388-98
12700232
J Virol. 1999 Dec;73(12):9984-91
10559312
J Biol Chem. 2006 May 12;281(19):13449-13462
16517592
Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):578-84
15637308
Nat Med. 2005 Jul;11(7):791-6
15951748
J Virol. 2006 Nov;80(22):11074-81
16956946
J Med Virol. 2002 Nov;68(3):335-42
12226819
J Virol. 2002 Apr;76(8):4008-21
11907240
RNA. 2004 Feb;10(2):321-9
14730030
J Virol. 2003 May;77(9):5487-92
12692249
J Virol. 2006 Mar;80(5):2418-28
16474148
J Gen Virol. 2006 Jul;87(Pt 7):1935-1945
16760395